Condition | Predict any subgroup analysis OR (95 % CI) | Predict subgroup analysis using appropriate methods OR (95 % CI) |
---|---|---|
Journal of publication | p = 0.60 | p = 0.15 |
 British Medical Journal | 1.00 | 1.00 |
 Annals | 1.28 (0.43, 3.82) | 7.12 (0.92, 55.31) |
 Journal of the American Medical Association | 1.34 (0.53, 3.35) | 2.40 (0.63, 8.37) |
 Lancet | 1.35 (0.60, 3.03) | 3.58 (1.18, 10.88) |
 New England Journal of Medicine | 1.90 (0.80, 4.48) | 2.28 (0.73, 7.11) |
Year of publication | p = 0.39 | p = 0.05 |
 Year | 1.04 (0.95, 1.15) | 0.88 (0.76, 1.00) |
Biostatistician as coauthor | p = 0.90 | p = 0.11 |
 No biostatistician as coauthor | 1.00 | 1.00 |
 Biostatistician as coauthor | 1.03 (0.63, 1.68) | 1.71 (0.89, 3.30) |
Medical condition under study | p = 0.10 | p = 0.02 |
 Obstetrics/gynecological | 1.00 | 1.00 |
 Cardiovascular | 2.47 (0.83, 7.35) | 2.30 (0.38, 14.02) |
 Infectious disease | 2.03 (0.61, 6.77) | 0.51 (0.08, 3.07) |
 Cancer | 3.60 (1.09, 11.84) | 0.46 (0.08, 2.67) |
 Psychiatry/neurology | 3.03 (0.87, 10.63) | 0.47 (0.07, 3.08) |
 Autoimmune, including DM | 3.53 (1.03, 12.16) | 0.71 (0.10, 4.98) |
 Pulmonary/critical care | 1.37 (0.36, 5.22) | 1.88 (0.22, 15.85) |
 Other chronic disease | 4.80 (1.41, 16.35) | 1.27 (0.18, 8.85) |
 Other, uncategorized | 1.29 (0.37, 4.45) | 3.07 (0.22, 43.87) |
First author’s region | p = 0.65 | p = 0.47 |
 Other | 1.00 | 1.00 |
 North America | 1.48 (0.65, 3.40) | 1.51 (0.56, 4.05) |
 Europe | 1.38 (0.63, 2.98) | 1.78 (0.71, 4.44) |
Funding | p = 0.01 | p = 0.007 |
 No industry funding | 1.00 | 1.00 |
 Industry funding | 1.94 (1.17, 3.21) | 0.39 (0.20, 0.77) |
Significance of the primary outcome | p = 0.022 | p = 0.19 |
 Not significant | 1.00 | 1.00 |
 Significant | 0.55 (0.33, 0.92) | 0.64 (0.33, 1.24) |
Sample size | p < 0.001 | p = 0.18 |
 Quintiles | 1.98 (1.64, 2.40) | 1.21 (0.91, 1.61) |